APTO

Aptose Biosciences

Last Updated:

Q3 '20

Price

quotes and stock data delayed 15 minutes

Cash

$82.7M

Burn Rate (Qtr)

$13.2M

Company Profile

At Aptose Biosciences, we are building a pipeline of novel and targeted oncology therapies with the potential to serve specific populations of cancer patients.
Our pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of conventional anti-cancer therapies through simultaneous targeting of key drivers of disease in cancer cells without overlapping toxicities and thus preserving the quality of life in cancer patients.

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information

Drug | Disease (links)

Stage (next event)

Catalyst Date

CG-806 (BTK Inhibitor)

B-cell malignancies (NHL & CLL)

Phase 1 (Data Presentation at ASH)

December 5, 2020

APTO-253

RR Acute Myelogenous Leukemia/ HR Myelodysplasia

Phase 1 (ASH Data Presentation)

Dec 5-8, 2020

Recent Posts

See what the community is saying - click to see full post

APTO EHA 2020

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon